These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
311 related items for PubMed ID: 15699307
1. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Arch Pediatr Adolesc Med; 2005 Feb; 159(2):139-44. PubMed ID: 15699307 [Abstract] [Full Text] [Related]
2. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613 [Abstract] [Full Text] [Related]
3. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Clark MK, Sowers MR, Nichols S, Levy B. Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863 [Abstract] [Full Text] [Related]
4. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density. Johnson CC, Burkman RT, Gold MA, Brown RT, Harel Z, Bruner A, Stager M, Bachrach LK, Hertweck SP, Nelson AL, Nelson DA, Coupey SM, McLeod A, Bone HG. Contraception; 2008 Apr; 77(4):239-48. PubMed ID: 18342646 [Abstract] [Full Text] [Related]
5. Effects of hormonal contraception on bone mineral density after 24 months of use. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563 [Abstract] [Full Text] [Related]
7. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Contraception; 2006 Aug; 74(2):90-9. PubMed ID: 16860045 [Abstract] [Full Text] [Related]
8. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Shaarawy M, El-Mallah SY, Seoudi S, Hassan M, Mohsen IA. Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229 [Abstract] [Full Text] [Related]
10. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Beksinska ME, Smit JA, Kleinschmidt I, Farley TM, Mbatha F. Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065 [Abstract] [Full Text] [Related]
16. Bone mineral density and depot medroxyprogesterone acetate. Albertazzi P, Bottazzi M, Steel SA. Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487 [Abstract] [Full Text] [Related]
18. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Sanches L, Marchi NM, Castro S, Juliato CT, Villarroel M, Bahamondes L. Contraception; 2008 Nov; 78(5):365-9. PubMed ID: 18929732 [Abstract] [Full Text] [Related]
19. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210 [Abstract] [Full Text] [Related]